Newsroom - Tevogen
6 days ago · Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company’s Precision Cell Therapy Platform
Tevogen Bio to Become Publicly Listed on NYSE via Business …
Jun 29, 2023 · Tevogen Holdings common stock and warrants are expected to be listed on the NYSE under the new ticker symbol “TVGN”. Tevogen Bio is currently focused on developing its pipeline using its precision T cell platform, ExacTcell.
Home - Tevogen
Nov 5, 2024 · Tevogen Bio is a late-stage biotech company harnessing the power of cytotoxic T lymphocytes (CTLs) with its ExacTcell platform. This pioneering technology produces scalable, rapidly available, unmodified allogeneic CTLs for the treatment of cancers, viral infections and the prevention of long-term complications of these conditions.
Technology - Tevogen
Tevogen’s commercial scale ready first generation manufacturing process already yields a highly efficient ratio of doses per cell donor. The second generation, Tevogen’s proprietary TCR-T process, is expected to dramatically increase the number of doses.
Press Releases Archive - Tevogen
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow Total eligible patients in the US exceed 2 million.
Tevogen Bio Inc. - Tevogen Bio Enters Into Agreement for Up to …
Jun 11, 2024 · Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts. WARREN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically ...
About - Tevogen
Tevogen’s focus on organizational and manufacturing efficiency is core to its successful biopharma business model and the company’s goal is to make personalized immunotherapies accessible to the masses for the first time.
Tevogen Bio Announces $8 Million Equity Investment
On February 14, 2024, Tevogen Bio Holdings Inc. (the “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, entered into a securities purchase agreement with an investor pursuant to which the investor ...
Tevogen Bio Reports First Quarter 2024 Financial Results
WARREN, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ...
Tevogen Bio Inc. - Tevogen Bio’s Founding CEO, Ryan Saadi, …
WARREN, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, filed a Registration Statement on Form S-1 (File No ...